Literature DB >> 17638134

Quantitation of human tissue and immune cell type II 14 kDa phospholipase A(2) by enzyme immunoassay.

B J Bolognese1, S D Holmes, L J McMillan, K F Kaiser, L A Marshall.   

Abstract

The metabolism of arachidonic acid into inflammatory mediators (e.g. prostaglandin, leukotrienes) is dependent upon the rate-limiting enzyme phospholipase A(2). Localization and quantification of type II 14 kDa phospholipase A(2) (PLA(2)) in cells or tissue preparations has historically been accomplished through activity measurements, a process that can provide variable results due to interference by exogenous substances with hydrolysis assessment. Others have reported on the use of sandwich enzyme immunoassays (EIA) to measure 14 kDa PLA(2) by mass in serum and exudate fluids, e.g. synovial fluid. Herein, we report the utilization of a human recombinant type II 14 kDa PLA(2) sandwich EIA to directly measure cell or tissue-residing 14 kDa PLA(2). It is known that type II 14 kDa PLA(2) resists acid treatment, and this technique was applied to cell fractions which liberated the enzyme from cellular membrane components prior to quantitation by EIA. Two human immune cell populations were assessed and shown to contain measurable levels of 14 kDa PLA(2). Neutrophil or monocyte cytosolic fractions contained no measurable levels whereas the respective 100 000g particulate fractions contained 2.6+/-0.8 pg (neutrophil) and 2.1+/-0.6 pg (monocyte) 14 kDa PLA(2)/mug protein. Human placenta cytosolic fractions contained no measurable levels while 100 000g particulate contained approximately 25 ng 14 kDa PLA(2)/mg protein. This EIA, in conjunction with acid extraction, provides an easy and reproducible assay to identify and quantify this enzyme in cells and whole tissues, expanding our ability to study the relationship of this enzyme to inflammatory processes.

Entities:  

Year:  1997        PMID: 17638134     DOI: 10.1007/s10787-997-0003-z

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   5.093


  31 in total

1.  Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A2.

Authors:  L A Marshall; J Bauer; M L Sung; J Y Chang
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

2.  The primary structure of a membrane-associated phospholipase A2 from human spleen.

Authors:  A Kanda; T Ono; N Yoshida; H Tojo; M Okamoto
Journal:  Biochem Biophys Res Commun       Date:  1989-08-30       Impact factor: 3.575

3.  Interleukin-1 beta induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostaglandin E2.

Authors:  K I Hulkower; S J Wertheimer; W Levin; J W Coffey; C M Anderson; T Chen; D L DeWitt; R M Crowl; W C Hope; D W Morgan
Journal:  Arthritis Rheum       Date:  1994-05

4.  Recombinant human secretory phospholipase A2: purification and characterization of the enzyme for active site studies.

Authors:  J M Stadel; C Jones; G P Livi; K Hoyle; J Kurdyla; A Roshak; M M McLaughlin; D A Pfarr; S Comer; J Strickler
Journal:  J Mol Recognit       Date:  1992-12       Impact factor: 2.137

5.  Human neutrophils store type II 14-kDa phospholipase A2 in granules and secrete active enzyme in response to soluble stimuli.

Authors:  M D Rosenthal; M N Gordon; E S Buescher; J H Slusser; L K Harris; R C Franson
Journal:  Biochem Biophys Res Commun       Date:  1995-03-17       Impact factor: 3.575

6.  Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid.

Authors:  J J Seilhamer; W Pruzanski; P Vadas; S Plant; J A Miller; J Kloss; L K Johnson
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

7.  Structure and properties of a human non-pancreatic phospholipase A2.

Authors:  R M Kramer; C Hession; B Johansen; G Hayes; P McGray; E P Chow; R Tizard; R B Pepinsky
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

8.  Characterization of phospholipase A2 release by elicited-peritoneal macrophage and its relationship to eicosanoid production.

Authors:  L A Marshall; B Bolognese; A Roshak
Journal:  J Lipid Mediat Cell Signal       Date:  1994-09

9.  Prostaglandin E2 requirement for transforming growth factor beta 1 inhibition of elicited macrophage 14 kDa phospholipase A2 release.

Authors:  M McCord; B Bolognese; L A Marshall
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Phospholipase A2 in juvenile rheumatoid arthritis: correlation to disease type and activity.

Authors:  W Pruzanski; K Albin-Cook; R M Laxer; J MacMillan; E Stefanski; P Vadas; E D Silverman
Journal:  J Rheumatol       Date:  1994-10       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.